08:00 , Mar 2, 2015 |  BioCentury  |  Strategy

Sosei finds its R&D engine

Sosei Group Corp. has only one clinical candidate in development, but the Japanese biotech may have found its R&D engine in drug discovery platform company Heptares Therapeutics Ltd. The M&A deal marks a clean break...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

Activus Pharma, Sosei deal

Sosei will acquire drug delivery company Activus. Sosei will gain Activus Pure Nano-particle Technology (APNT), which can yield highly pure 50-300 nm particles for use in injections, ophthalmic solutions and inhalations of poorly soluble compounds....
07:00 , Jun 28, 2010 |  BioCentury  |  Strategy

Sosei's Consolidation Play

Japanese biotech and pharma companies, including Sosei Group Corp., have tended to build their businesses by acquiring foreign assets. Sosei's acquisition of Activus Pharma Co. Ltd., a Japanese nanoparticle-based formulation company, breaks the mold. The...
07:00 , Jun 28, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Celgene Corp. (NASDAQ:CELG) gained $0.72 to $56.07 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Revlimid lenalidomide in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM). Genmab A/S...
23:45 , Jun 22, 2010 |  BC Extra  |  Company News

Sosei to acquire Activus

Sosei Group Corp. (Tokyo:4565) will acquire drug delivery company Activus Pharma Co. Ltd. (Chiba, Japan) for up to Y500.3 million ($5.5 million) in cash and up to Y1 billion ($11 million) in future payments. Sosei...